Publications
Healthcare
Insights
In our most recent case studies, market research reports, conference talks, and other publications, we share and visualize our market insights.
Publications
In our most recent case studies, market research reports, conference talks, and other publications, we share and visualize our market insights.
The whitepaper “Digital Health Applications (DiGA) in Portugal,” explores the necessity and current status of implementing a DiGA framework in Portugal, offering expert insights and strategic recommendations for enhancing healthcare through digital solutions.
Discover the Transformative Reimbursement Pathways in Pediatric Healthcare through Our Engaging Webinar. Learn about the key aspects, benefits, and processes for achieving reimbursement for innovative healthcare solutions.
The sales force is and remains an essential sales driver for pharmaceutical companies. But not just since the coronavirus has it become clear that the traditional sales force is in urgent need of an update.
The Advanced Diabetes Technology Landscape 2024 is an extensive overview of companies shaping the future of diabetes care.
The Whitepaper “Enhancing HCP Engagement in Germany” showcases the evolving landscape of HCP engagement, explaining the shift from traditional face-to-face interaction to dynamic digital strategies.
Discover the transformative DiGA fast-track in digital health through our engaging webinar. Learn about its impact, benefits, and the process for digital solutions certification.
In “5 Insights on Artificial Intelligence (AI),” Tobias Woldrich answers the most relevant questions about Artificial Intelligence and its potential within companies.
In “6 Insights on PECAN” our PECAN expert Vincent Erdmann answers the most relevant questions of the PECAN process in France.
In “9 Insights on Sales Force Performance Boost”, our partner Torsten Christann answers the most relevant questions about the Sales Boost and its benefits for companies.
In “7 Insights on DiGA”, our DiGA expert Alexander Voigt provides answers to the most relevant questions about DiGA.
In “8 Insights on Prequalification”, our expert Dr. Sigrid Bender answers the most relevant questions about the prequalification process.
Great news for Digital Health in Germany: After DiGA, Digital Care Applications (=DiPA) are now also coming into the care sector.
With our expertise in DiGA approval and our international network, we support our customers in all issues related to the PECAN process.
In an extensive article in PM-Report, Germany’s most significant pharma magazine, Digital Oxygen’s experts provide a 360° overview of DiGA in the context of pharma.
Our clients have a plethora of options when it comes to engaging with digital health providers.
The Advanced Diabetes Technology Landscape 2023 is an extensive overview of companies shaping the future of diabetes care.
There are high hopes that 6G will revolutionize digital health. Axel Meiling provides insights why 6G per se won’t be the solution – and what the actual blockers for digital health are.
One aspect of DiGA is frequently left out in recent reports: The unknown number of DiGA prescriptions – the part of the DiGA iceberg that is not visible.
At the panel discussion at this year’s Med-Tech World in Malta, the question was discussed: Does digitalization succeed in creating health equality?
With the DiPA Canvas, Digital Oxygen provides a straight-forward tool for the self-assessment of essential questions for any DiPA manufacturer.
The DiGA Canvas is a comprehensive tool to assess the crucial questions, challenges, and requirements for your DiGA.
In this article, Torsten Christann comments on the importance, opportunities, and downsides of data for the pharma industry’s future business models.
The Advanced Diabetes Technology Landscape 2022 gives a structured overview of the companies shaping the future of Diabetes Care.
There is a trend of DiGA start-ups looking for corporate partners and vice versa. But why?
Our case study and framework showcases the relevant dimensions and questions to be asked when considering a DiGA acquisition.
Sensors, wearables, apps: Torsten Christann comments on the opportunities of self-measurement for the generation of Real-World-Evidence in Market Access processes.
In this article, Torsten Christann addresses the question whether pharma corporations should add DiGA to their portfolio or no.
At WIG2 Digital Health Conference, Healthcare Expert Alexander Voigt talked about what matters after the regulatory market access: Reaching patients.
This study examines the pain points and inefficiencies of diabetes care in German hospitals – and how there is a case for Glucometry MedTechs to disrupt the industry.
Clients and Partners